Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic Dyslipidemia

This publication has 17 references indexed in Scilit:

• The nicotinic acid receptor–a new mechanism for an old drug
  The Lancet, 2004
• Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome
  Clinical Pharmacology & Therapeutics, 2003
• Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content
  Metabolism, 2003
• Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
  The American Journal of Cardiology, 2003
• Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid
  Journal of Biological Chemistry, 2003
• PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect
  Nature Medicine, 2003
• Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial
  Archives of internal medicine (1960), 2002
• Mechanistic studies of high-density lipoproteins
  The American Journal of Cardiology, 1998
• Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders
  Scandinavian Journal of Clinical and Laboratory Investigation, 1996
• Inhibition of the Mobilization of Free Fatty Acids from Adipose Tissue in Diabetes
  Acta Medica Scandinavica, 1965